Radiopharm Theranostics logo

Radiopharm Theranostics(NASDAQ) RADX

Market Cap$17.74MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)-94%
5 YearN/A
1 Year-85%
1 Month-46%
$1.13
+1.80%
+0.02Today
Radiopharm Theranostics last closing stock price
MetricPriceDate
Last closeUSD 1.132026-10-09
Radiopharm Theranostics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-20.42%USD 1.422026-10-02
1 month-45.67%USD 2.082026-09-09
3 month-74.14%USD 4.372026-07-10
Year to date-78.35%USD 5.222025-12-31
1 year-84.83%USD 7.452025-10-09
Since inception-93.6%USD 17.672024-12-05

Radiopharm Theranostics Financials at a Glance

Market Cap

$17.74MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

N/A

Net Income (TTM)

N/A

EPS (TTM)

-$3.17

P/E Ratio

-0.36

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$1.13

Volume

65,762

Open

$1.10

Previous Close

$1.13

Daily Range

$1.06 - $1.24

52-Week Range

$1.00 - $16.25

Estimated Earnings Date

Feb 26, 2027

RADX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Radiopharm Theranostics

Radiopharm Theranostics Limited is an innovative biotechnology company based in Australia, focused on developing advanced radiopharmaceutical treatments. Established in 2021, the company aims to fill critical healthcare gaps through its diverse pipeline of products designed for diagnostic imaging and therapeutic interventions.

Products and Services
  • RAD 204 targets PD-L1 for non-small cell lung cancer
  • RAD 202 is aimed at HER2 for breast cancer and solid tumors
  • RAD 301 and RAD 302 focus on pancreatic cancer diagnostics and treatment
Growth Outlook
  • Strategic partnership with Lantheus Holdings accelerates clinical development
  • Pipeline includes multiple promising candidates for various cancers
  • Market demand for radiopharmaceuticals is expected to grow significantly
Financial Highlights
  • Recent quarterly revenue of 1,401,852 AUD shows potential for growth
  • Cash and cash equivalents increased to 4,138,308 AUD in the latest quarter
  • Operating expenses reflect ongoing investment in research and development
Radiopharm Theranostics Limited is positioned in a rapidly evolving sector, with a focus on addressing unmet medical needs through its innovative products. The company's strategic partnerships and diverse pipeline provide a solid foundation for future growth. Recent financial data indicates a commitment to advancing its research initiatives, while the increasing market demand for radiopharmaceuticals presents significant opportunities. Investors may find the company's trajectory compelling as it continues to develop solutions for challenging medical conditions.
AI Generated • Sep 26, 2026

Industry

Biotechnology

Sector

Health Care

Employees

14

CEO

Riccardo Canevari

Website

radiopharmtheranostics.com

Headquarters

Carlton, VIC 3053, AU

RADX Financials

Key Financial Metrics (TTM)

Gross Margin

-39.41%

Operating Margin

-2545.78%

Net Income Margin

-1992.46%

Return on Equity

-144.24%

Return on Capital

-270.71%

Return on Assets

-91.71%

Earnings Yield

-2.78%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$17.74MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

15.70M

Volume

65.76K

Avg. Volume

84.56K

Financials (TTM)

Gross Profit

-A$1.07M

Operating Income

-A$70.45M

EBITDA

-A$69.12M

Operating Cash Flow

-A$76.56M

Capital Expenditure

A$32.08M

Free Cash Flow

-A$44.47M

Cash & ST Invst.

A$4.14M

Total Debt

A$0.00

Radiopharm Theranostics Performance Analysis

Radiopharm Theranostics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 196,671N/A
20242024-06-30AUD 196,107-0.3%
20252025-06-30AUD 2,353,1171099.9%
20262026-06-30AUD 1,875,584-20.3%
Radiopharm Theranostics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12024-09-30N/A
Q22024-12-31N/A
Q22025-12-31N/A
Q42026-06-30N/A
Radiopharm Theranostics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -21.57-8.8%
20242024-06-30AUD -24.3913.1%
20252025-06-30AUD -3.43-86.0%
20262026-06-30AUD -3.656.4%
Radiopharm Theranostics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12024-09-30N/A
Q22024-12-31N/A
Q22025-12-31N/A
Q42026-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

A$1.40M

N/A

Gross Profit

A$162.57K

N/A

Gross Margin

11.60%

N/A

Market Cap

$17.74MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.27M

N/A

Employees

14

N/A

Net Income

-A$28.58M

N/A

EBITDA

-A$39.91M

N/A

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

A$4.14M

+118.5%

Total Debt

A$0.00

N/A

Accounts Receivable

A$17.45M

+295.7%

Inventory

A$0.00

N/A

Long Term Debt

A$0.00

N/A

Short Term Debt

A$0.00

N/A

Return on Assets

-91.71%

N/A

Return on Invested Capital

-1.71%

N/A

Free Cash Flow

A$0.00

+100.0%

Operating Cash Flow

-A$32.08M

-355.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CYCNCyclerion Therapeutics, Inc.
$23.52+0.00%
KTTAPasithea Therapeutics Corp.
$0.47+6.03%
BCLIBrainstorm Cell Therapeutics Inc.
$0.95+4.40%
QNRXQuoin Pharmaceuticals, Ltd.
$4.50-1.10%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$34.39+1.78%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$139.76-1.94%
WFFWf
$12.29+499.51%
IRENIren
$35.19-1.46%

Questions About RADX

What is the current price of Radiopharm Theranostics?

Radiopharm Theranostics is trading at $1.13 per share.

What is the 52-week range for Radiopharm Theranostics?

Over the past 52 weeks, Radiopharm Theranostics has traded between $1.00 and $16.25.

How much debt does Radiopharm Theranostics have?

As of the most recent reporting period, Radiopharm Theranostics reported total debt of A$0.00.

How much cash does Radiopharm Theranostics have on hand?

Radiopharm Theranostics reported A$2.87M in cash and cash equivalents in its most recent financial results.

What is Radiopharm Theranostics’s dividend yield?

Radiopharm Theranostics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services